on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics: Financial Update and Progress on AAC
On April 7, 2026, GenSight Biologics disclosed its cash position and revenues obtained through its Compassionate Access Authorization (CAA) program as of March 31, 2026. The company had €3.2 million in cash, compared to €2.4 million in December 2025, notably thanks to a €1.7 million equity fundraising.
The AAC program generated €2.6 million in revenue in March 2026, with a treatment cost of €425,000 per injection. GenSight expects the revenue from these programs to cover its annual operating expenses, excluding the costs of a new clinical trial. Several treatments are planned for April, as well as the launch of a program in Israel in the second quarter of 2026.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news